Atea Pharmaceuticals Inc. (AVIR)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
CEO:
Jean-Pierre Sommadossi
Employees:
60
125 SUMMER STREET, 16TH FLOOR, BOSTON, MA 02110
857-204-8109

Atea Pharmaceuticals, Inc. focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trials for dengue; AT-777, an NS5A inhibitor, and AT-281, a pharmaceutically acceptable salt.

Data derived from most recent annual or quarterly report
Market Cap 482.894 Million Shares Outstanding83.258 Million Avg 30-day Volume 595.892 Thousand
P/E Ratio38.0735 Dividend Yield0.0 EPS-1.74
Price to Revenue2.6273 Debt to Equity0.0 EBITDA24.629 Million
Price to Book Value0.895 Operating Margin10.9182 Enterprise Value-93.351 Million
Current Ratio27.461 EPS Growth-0.903 Quick Ratio27.263
1 Yr BETA 1.2454 52-week High/Low 46.91 / 5.31 Profit Margin6.9007
Operating Cash Flow Growth-147.667 Altman Z-Score12.0222 Free Cash Flow to Firm -179.82 Million
View SEC Filings from AVIR instead.

View recent insider trading info

Funds Holding AVIR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AVIR

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BERGER FRANKLIN M

  • Director
61,264 2022-06-17 1

DUNCAN BARBARA GAYLE

  • Director
61,264 2022-06-17 1

POLSKY BRUCE

  • Director
61,264 2022-06-17 1

MURPHY POLLY A.

  • Director
61,264 2022-06-17 2

LUCIDI BRUNO

  • Director
61,264 2022-06-17 1

ADAMS JEROME M.

  • Director
61,264 2022-06-17 1

SOMMADOSSI JEAN-PIERRE PRESIDENT, CEO, AND CHAIRMAN

  • Officer
  • Director
378,033 2022-01-31 1

CORCORAN ANDREA SEE REMARKS

  • Officer
181,000 2022-01-31 1

FOSTER WAYNE EVP, CHIEF ACCOUNTING OFFICER

  • Officer
120,000 2022-01-31 1

HORGA MARIA ARANTXA CHIEF MEDICAL OFFICER

  • Officer
170,000 2022-01-31 1

VAVRICKA JOHN CHIEF COMMERCIAL OFFICER

  • Officer
135,000 2022-01-31 1

HAMMOND JANET MJ CHIEF DEVELOPMENT OFFICER

  • Officer
190,000 2022-01-31 1

ROCK SPRINGS CAPITAL MANAGEMENT LP

ROCK SPRINGS CAPITAL MASTER FUND LP

ROCK SPRINGS CAPITAL LLC

  • 10% Owner
No longer subject to file 2020-11-03 0

HACK ANDREW A. F.

  • Director
5,615,659 2020-11-03 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 22:15:03 UTC 2.6458 0.4242 1800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 21:45:03 UTC 2.6458 0.4242 1800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 21:15:03 UTC 2.6458 0.4242 1800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 20:45:03 UTC 2.6458 0.4242 1800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 20:15:06 UTC 2.6458 0.4242 1800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 19:45:03 UTC 2.6458 0.4242 1800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 19:15:03 UTC 2.6458 0.4242 1800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 18:45:03 UTC 2.6458 0.4242 1800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 18:15:04 UTC 2.6458 0.4242 1800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 17:45:04 UTC 2.6458 0.4242 1800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 17:15:04 UTC 2.6458 0.4242 1800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 16:45:03 UTC 2.6253 0.4447 1800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 16:15:03 UTC 2.6253 0.4447 1800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 15:45:03 UTC 2.6253 0.4447 1800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 15:15:03 UTC 2.6253 0.4447 1800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 14:45:03 UTC 1.8753 0.4447 1800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 14:15:03 UTC 1.8753 0.4447 1800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 13:45:03 UTC 1.8753 0.4447 1800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 13:15:03 UTC 1.8753 0.4447 800000
ATEA PHARMACEUTICALS INC AVIR 2022-09-23 12:45:03 UTC 1.8753 0.4447 800000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments